About The Study: Receiving at least two doses of wild-type BNT162b2 vaccine (Pfizer) was associated with a reduced risk of COVID-19 emergency department or urgent care and outpatient visits in children younger than five years. The risk of SARS-CoV-2 encounters appeared lower for those with two versus three doses of BNT162b2, albeit with wide CIs, which is likely due to more immune-evasive Omicron sublineages (e.g., BQ.1-related and XBB-related strains) becoming dominant by the time young children received their third dose and longer median time since dose three compared with dose two.
Authors: Sara Y. Tartof, Ph.D., M.P.H., of the Kaiser Permanente Southern California Department of Research & Evaluation in Pasadena, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.17473?guestAccessKey=3c77918c-2e4c-42f9-b7e9-84eed4b3aa00&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091523